Physician profile
David Howell
NPI 1952379810
$1,677.75
in general payments reported to CMS, 2019-2025
21 companies · $46.25 in 2025
The $46.25 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $206 · 2020: $189 · 2021: $424 · 2022: $266 · 2023: $279 · 2024: $266 · 2025: $46.25.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $592.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $592.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $345.70 | 2019-2024 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $203.15 | 2021-2022 | |
| Pfizer INC. | $180.54 | 2019-2024 | |
| Seqirus USA INC | $124.76 | 2021-2023 | Flucelvax Quadrivalent |
| Supernus Pharmaceuticals, INC. | $117.53 | 2021-2023 | Qelbree |
| Sobi, INC | $76.81 | 2020-2023 | |
| Glaxosmithkline, LLC. | $74.12 | 2019-2024 | Rotarix, Bexsero |
| Corium, LLC | $68.44 | 2023-2024 | Azstarys |
| Ironshore Pharmaceuticals INC. | $66.64 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $65.15 | 2022-2024 | Flumist Quadrivalent |
| Teva Pharmaceuticals USA, INC. | $57.07 | 2021 | |
| Verrica Pharmaceuticals INC. | $45.84 | 2023 | Ycanth |
| Cranial Technologies, INC | $44.61 | 2024 | Doc Band |
| Sanofi Pasteur INC. | $40.96 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.04 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $33.16 | 2022 | |
| Mayne Pharma Commercial LLC | $23.03 | 2023 | |
| Hologic Sales and Service, LLC | $22.29 | 2025 | Aptima |
| Phadia US INC. | $18.82 | 2019 | |
| Alexion Pharmaceuticals, INC. | $18.53 | 2023 | Strensiq |
| Dermira, INC. | $16.56 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Howell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.